# US 2023/0058982 A1 · Anti-ctla-4 antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058982 A1
- Document ID: US20230058982A1
- Status: Published application
- Kind: A1
- Application number: 17/788,998
- Filed: 2019-12-27
- Published: 2023-02-23
- Earliest claimed: 2019-12-27
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Hitoshi KATADA; Kanako TATSUMI; Kanako ATSUMI; Shun SHIMIZU; Masaki KAMIMURA; Yasunori KOMORII; Yuji HORI; Tomoyuki IGAWA; Hiroki KAWAUCHI; Hiroaki SUSUMU
- Web page: https://patentgrep.com/patent/US20230058982A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/00: Antineoplastic agents
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.

## Claims

### Claim 1

An anti-CTLA-4 antibody having a CTLA-4 binding activity that is dependent on the concentration of an adenosine-containing compound, wherein the antibody has at least one feature selected from (a) to (i) below:
(a) a binding activity in the presence of 100 μM adenosine-containing compound is two times or more higher than that in the absence of the adenosine-containing compound;
(b) KD value in the presence of 100 μM adenosine-containing compound is 5×10−7 M or less;
(c) KD value in the absence of the adenosine-containing compound is 1×10−6 M or more;
(d) forming a ternary complex with the adenosine-containing compound and CTLA-4;
(e) binding to a region from the amino acid at position 97 to the amino acid at position 106 of the human CTLA-4 (extracellular domain, SEQ ID NO: 28);
(f) competing with ABAM004 (VH, SEQ ID NO: 10; and VL, SEQ ID NO: 11) for binding to CTLA-4;
(g) binding to the same epitope as that of ABAM004 (VH, SEQ ID NO: 10; and VL, SEQ ID NO: 11);
(h) showing cytotoxic activity against a CTLA-4-expressing cell; and
(i) binding to human- and mouse-derived CTLA-4.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody comprises: (a) HVR-H1 (SEQ ID NO: 223) comprising the amino acid sequence SX1TMN, wherein X1 is H, A, R, or K; (b) HVR-H2 (SEQ ID NO: 224) comprising the amino acid sequence SISX1X2SX3YIYYAX4SVX5G, wherein X1 is S or T, X2 is R or Q, X3 is G or H, X4 is D, E, or R, and X5 is K or R; and (c) HVR-H3 (SEQ ID NO: 225) comprising the amino acid sequence YGX1REDMLWVFDY, wherein X1 is K or A.

### Claim 3 (depends on 2)

The antibody of claim 2, which further comprises: (a) HVR-L1 (SEQ ID NO: 226) comprising the amino acid sequence X1GX2STX3VGDYX4X5VX6, wherein X1 is T, D, Q, or E, X2 is T or P, X3 is D or G, X4 is N or T, X5 is Y or W, and X6 is S or H; (b) HVR-L2 (SEQ ID NO: 227) comprising the amino acid sequence X1TX2X3KPX4, wherein X1 is E, F, or Y, X2 is S or I, X3 is K or S, and X4 is S, E, or K; and (c) HVR-L3 (SEQ ID NO: 228) comprising the amino acid sequence X1TYAAPLGPX2, wherein X1 is S or Q and X2 is M or T.

### Claim 4 (depends on 1)

The antibody of claim 1, which comprises: (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 83 to 86, 98, and 135 to 141; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 88 to 95, 97, 99, 134, and 144 to 149; or (c) a VH sequence having the amino acid sequence of any one of SEQ ID NOs: 83 to 86, 98, and 135 to 141 and a VL sequence having the amino acid sequence of any one of SEQ ID NOs: 88 to 95, 97, 99, 134, and 144 to 149.

### Claim 5 (depends on 1)

A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 6

-7. (canceled)

### Claim 8

A polypeptide, which comprises a variant Fc region comprising amino acid alterations in a parent Fc region, wherein the parent Fc region is composed of two polypeptide chains, and wherein the variant Fc region comprises amino acid alterations at the following positions:
(i) positions 234, 235, 236, 239, 250, 268, 270, 298, 307, and 326 according to EU numbering in a first polypeptide of the parent Fc region; and
(ii) positions 236, 250, 270, 298, 307, 326, and 334 according to EU numbering in a second polypeptide of the parent Fc region.

### Claim 9 (depends on 8)

The polypeptide of claim 8, wherein the binding activity to at least one Fcγ receptor selected from the group consisting of FcγRIa, FcγRIIa, FcγRIIb, and FcγRIIIa is enhanced in the variant Fc region compared to that in the parent Fc region.

### Claim 10 (depends on 8)

The polypeptide of claim 8, wherein the selectivity between an activating Fcγ receptor and an inhibitory Fcγ receptor is improved in the variant Fc region compared to that in the parent Fc region.

### Claim 11 (depends on 3)

The antibody of claim 3, which comprises:
(1) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 100; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 101; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 113; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 114; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 115;
(2) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 100; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 104; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 116; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 115;
(3) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 105; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 106; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133;
(4) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 108; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 121; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 123; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 153;
(5) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 110; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 122; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133;
(6) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 112; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 128; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133;
(7) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 111; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 152; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 128; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133;
(8) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 112; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 129; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133;
(9) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 111; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 152; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 129; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133; or
(10) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 107; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 109; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 102; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 130; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 117; and (f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 133.

### Claim 12

An anti-CTLA-4 antibody, which comprises:
(1) a VH sequence as set forth in SEQ ID NO: 98 and a VL sequence as set forth in SEQ ID NO: 99;
(2) a VH sequence as set forth in SEQ ID NO: 83 and a VL sequence as set forth in SEQ ID NO: 97;
(3) a VH sequence as set forth in SEQ ID NO: 86 and a VL sequence as set forth in SEQ ID NO: 134;
(4) a VH sequence as set forth in SEQ ID NO: 136 and a VL sequence as set forth in SEQ ID NO: 95;
(5) a VH sequence as set forth in SEQ ID NO: 140 and a VL sequence as set forth in SEQ ID NO: 146;
(6) a VH sequence as set forth in SEQ ID NO: 141 and a VL sequence as set forth in SEQ ID NO: 146;
(7) a VH sequence as set forth in SEQ ID NO: 140 and a VL sequence as set forth in SEQ ID NO: 147;
(8) a VH sequence as set forth in SEQ ID NO: 141 and a VL sequence as set forth in SEQ ID NO: 147;
(9) a VH sequence as set forth in SEQ ID NO: 136 and a VL sequence as set forth in SEQ ID NO: 149;
(10) a first variable region comprising a VH sequence as set forth in SEQ ID NO: 140 and a VL sequence as set forth in SEQ ID NO: 146 and a second variable region comprising a VH sequence as set forth in SEQ ID NO: 141 and a VL sequence as set forth in SEQ ID NO: 146; or
(11) a first variable region comprising a VH sequence as set forth in SEQ ID NO: 140 and a VL sequence as set forth in SEQ ID NO: 147 and a second variable region comprising a VH sequence as set forth in SEQ ID NO: 141 and a VL sequence as set forth in SEQ ID NO: 147.

### Claim 13 (depends on 1)

An isolated nucleic acid encoding the anti-CTLA-4 antibody of claim 1.

### Claim 14 (depends on 13)

A vector comprising the nucleic acid of claim 13.

### Claim 15 (depends on 13)

A host cell comprising the nucleic acid of claim 13.

### Claim 16 (depends on 15)

A method of making an anti-CTLA-4 antibody comprising culturing the host cell of claim 15 under conditions suitable for expression of the anti-CTLA-4 antibody.

### Claim 17 (depends on 1)

A method of treating a tumor comprising administering the anti-CTLA-4 antibody of claim 1 to an individual having a tumor.

### Claim 18 (depends on 1)

A method of damaging a Treg cell in an individual comprising administering the anti-CTLA-4 antibody of claim 1 to an individual.
